Research Summary

I am a medical oncologist with a PhD in cell and molecular biology. I maintain an active academic clinical practice and lead a basic and translational research laboratory focused on cancer genetics, precision medicine, and the molecular basis of targeted therapy response and resistance. I have discovered several mechanisms of resistance to EGFR-targeted therapy, BRAF- and MEK-targeted therapy, and ALK-targeted therapy in lung and other cancers. I direct a multi-disciplinary team engaged in laboratory-based patient-focused research, and I am an investigator on clinical trials, including rational upfront polytherapy trials designed to forestall and eliminate resistance and that are motivated by my laboratory-based discoveries.

Research Funding

  • July 1, 2019 - June 30, 2024 - (PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA231300
  • February 1, 2013 - January 31, 2024 - Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA169338
  • September 30, 2017 - August 31, 2022 - Bay Area Team Against Resistance, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: U54CA224081
  • August 10, 2017 - July 31, 2022 - The Cancer Target Discovery and Development Network at UCSF, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: U01CA217882


Vanderbilt University, B.S., 1998, Molecular Biology
New York University, School of Medicine, Ph.D., 2004, Cell and Mol. Biology
New York University, School of Medicine, M.D., 2005, Medicine
Brigham and Women’s Hospital/Harvard, 2005-2007, Internal Medicine
Memorial Sloan-Kettering Cancer Center, 2007-2011, Medical Oncology

Honors & Awards

  • 1998
    Vanderbilt University Honors Degree in Molecular Biology
  • 1998
    Vanderbilt University Research Excellence Award
  • 1998-2005
    NIH Medical Scientist Training Program Award
  • 2005
    Medical Science Writing Award, NYU School of Medicine
  • 2007
    US Patent 20060083742 Prenyl-electrostatic Switch
  • 2008-2010
    Charles A. Dana Foundation Clinical Scholars Research Fellowship
  • 2009
    Julia Zelmanovich Young Alumnus Award, NYU School of Medicine
  • 2010
    American Society of Clinical Oncology Young Investigator Award
  • 2010
    Uniting Against Lung Cancer Research Investigator
  • 2011
    NIH/NCI Clinical Investigator Career Development Award (K08)
  • 2012
    National Lung Cancer Partnership Young Investigator Award
  • 2012
    Sidney Kimmel Foundation Kimmel Scholar Award
  • 2012
    Damon Runyon Clinical Investigator Award Finalist
  • 2012
    Doris Duke Clinical Scientist Development Award
  • 2012
    American Lung Association Lung Cancer Discovery Award
  • 2012
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2012
    Visiting Scholar Howard Hughes Medical Institute (HHMI) Scholars Program at California, State University-Fullerton
  • 2012
    NIH Director's New Innovator Award (DP2)
  • 2013
    Searle Scholar Award
  • 2014
    Lung Cancer Innovators Award (Addario and Van Auken Foundations)
  • 2015
    Pew-Stewart Scholar, Pew Charitable Trust

Selected Publications

  1. Gui P, Bivona TG. Evolution of metastasis: new tools and insights. Trends Cancer. 2021 Dec 03.  View on PubMed
  2. Barbosa Rabago D, Blakely CM, Haderk F, Bivona TG. Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. J Vis Exp. 2021 Nov 22; (177).  View on PubMed
  3. Wu Q, Luo X, Terp MG, Li Q, Li Y, Shen L, Chen Y, Jacobsen K, Bivona TG, Chen H, Zeng R, Ditzel HJ. DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma. Mol Cancer. 2021 08 26; 20(1):108.  View on PubMed
  4. Zaman A, Bivona TG. Targeting AXL in NSCLC. Lung Cancer (Auckl). 2021; 12:67-79.  View on PubMed
  5. Zaman A, Wu X, Lemoff A, Yadavalli S, Lee J, Wang C, Cooper J, McMillan EA, Yeaman C, Mirzaei H, White MA, Bivona TG. Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer. Cell Rep. 2021 Aug 03; 36(5):109491.  View on PubMed
  6. Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 Oct; 16(10):1647-1662.  View on PubMed
  7. Gui P, Bivona TG. Stepwise evolution of therapy resistance in AML. Cancer Cell. 2021 Jul 12; 39(7):904-906.  View on PubMed
  8. Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Huang B, Bivona TG. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell. 2021 May 13; 184(10):2649-2664.e18.  View on PubMed
  9. Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JS. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science. 2021 02 26; 371(6532).  View on PubMed
  10. Kerr DL, Haderk F, Bivona TG. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Curr Opin Chem Biol. 2021 06; 62:1-12.  View on PubMed
  11. Nothdurft S, Thumser-Henner C, Breitenbücher F, Okimoto RA, Dorsch M, Opitz CA, Sadik A, Esser C, Hölzel M, Asthana S, Forster J, Beisser D, Kalmbach S, Grüner BM, Bivona TG, Schramm A, Schuler M. Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis. 2020 Nov 19; 9(11):102.  View on PubMed
  12. Liu J, Mayekar MK, Wu W, Yan M, Guan H, Wang J, Zaman A, Cui Y, Bivona TG, Choudhry H, Xing Q, Cao W. Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G. Cancer Lett. 2020 11 28; 493:217-227.  View on PubMed
  13. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020 09 03; 182(5):1232-1251.e22.  View on PubMed
  14. Cao W, Lee H, Wu W, Zaman A, McCorkle S, Yan M, Chen J, Xing Q, Sinnott-Armstrong N, Xu H, Sailani MR, Tang W, Cui Y, Liu J, Guan H, Lv P, Sun X, Sun L, Han P, Lou Y, Chang J, Wang J, Gao Y, Guo J, Schenk G, Shain AH, Biddle FG, Collisson E, Snyder M, Bivona TG. Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nat Commun. 2020 07 22; 11(1):3675.  View on PubMed
  15. Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. J Thorac Oncol. 2020 10; 15(10):1611-1623.  View on PubMed
  16. Bivona TG. EGFR targeted therapy resistance: current status, challenges, and future outlook. J Thorac Dis. 2020 May; 12(5):2849-2850.  View on PubMed
  17. Fan Q, An Z, Wong RA, Luo X, Lu ED, Baldwin A, Mayekar MK, Haderk F, Shokat KM, Bivona TG, Weiss WA. Betacellulin drives therapy resistance in glioblastoma. Neuro Oncol. 2020 04 15; 22(4):457-469.  View on PubMed
  18. Lotsberg ML, Wnuk-Lipinska K, Terry S, Tan TZ, Lu N, Trachsel-Moncho L, Røsland GV, Siraji MI, Hellesøy M, Rayford A, Jacobsen K, Ditzel HJ, Vintermyr OK, Bivona TG, Minna J, Brekken RA, Baguley B, Micklem D, Akslen LA, Gausdal G, Simonsen A, Thiery JP, Chouaib S, Lorens JB, Engelsen AST. AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 06; 15(6):973-999.  View on PubMed
  19. Zargar A, Chang S, Kothari A, Snijders AM, Mao JH, Wang J, Hernández AC, Keasling JD, Bivona TG. Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy. Chronic Dis Transl Med. 2019 Dec; 5(4):258-266.  View on PubMed
  20. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449.  View on PubMed

Go to UCSF Profiles, powered by CTSI